Sunday 15 November 2026
Export BRVE’s income statement to Excel — free account
Braveheart Bio, Inc.
BRVE- EPS
- n/m
- Free cash flow
- n/m
Quarter to September 2026, against a year earlier
19.62
0.88
−4.29%
Follow BRVE
Alert me
Analysts’ price targets Wall Street, collected weekly
Analyst price targets
Free accountTen years at a glance
| Ten-year view | Analyst estimates Powerpack | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM Sep ’26 | Trend | 10 yrs | 2026e | 2027e | 2028e | Next 3/yr |
| Income, $m | ||||||||||||||||||
| Income, $m | Revenue | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Gross margin, % | — | — | — | — | — | — | — | — | — | — | — | — | ||||||
| EBT | — | — | — | — | — | — | — | — | — | (66) | (62) | — | ||||||
| EBT margin, % | — | — | — | — | — | — | — | — | — | 0.00 | 0.00 | — | ||||||
| Net income | — | — | — | — | — | — | — | — | — | (66) | (62) | — | ||||||
| Per share, $ | ||||||||||||||||||
| Per share, $ | Revenue | — | — | — | — | — | — | — | — | — | 0.00 | 0.00 | — | |||||
| Earnings | — | — | — | — | — | — | — | — | — | (17.20) | (12.11) | — | ||||||
| Cash flow | — | — | — | — | — | — | — | — | — | (0.52) | (0.92) | — | ||||||
| Capex | — | — | — | — | — | — | — | — | — | 0.00 | 0.00 | — | ||||||
| Free cash flow | — | — | — | — | — | — | — | — | — | (0.52) | (0.92) | — | ||||||
| Book value | — | — | — | — | — | — | — | — | — | (17.15) | 9.55 | — | ||||||
| Shares, m | — | — | — | — | — | — | — | — | — | 4 | 18 | — | ||||||
| Valuation, × | ||||||||||||||||||
| Valuation, × | P/E | — | — | — | — | — | — | — | — | — | — | 0 | — | |||||
| P/S | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| P/B | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| EV/Sales | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| EV/FCF | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| Cash, $m | ||||||||||||||||||
| Cash, $m | Operating cash flow | — | — | — | — | — | — | — | — | — | (2) | (48) | — | |||||
| Capex | — | — | — | — | — | — | — | — | — | — | — | — | ||||||
| Free cash flow | — | — | — | — | — | — | — | — | — | (2) | (48) | — | ||||||
| Balance, $m | ||||||||||||||||||
| Balance, $m | Working capital | — | — | — | — | — | — | — | — | — | 84 | 343 | — | |||||
| Net debt | — | — | — | — | — | — | — | — | — | (89) | (349) | — | ||||||
| Shareholders’ equity | — | — | — | — | — | — | — | — | — | (66) | 498 | — | ||||||
| Returns, % | ||||||||||||||||||
| Returns, % | ROA | — | — | — | — | — | — | — | — | — | 0.00 | 0.00 | — | |||||
| ROIC | — | — | — | — | — | — | — | — | — | 0.00 | (28.66) | — | ||||||
| ROE | — | — | — | — | — | — | — | — | — | 0.00 | 0.00 | — | ||||||
| People | ||||||||||||||||||
| People | Employees | — | — | — | — | — | — | — | — | — | 30 | — | — | |||||
| Revenue/emp, $m | — | — | — | — | — | — | — | — | — | 0.00 | — | — | ||||||
Negative figures in brackets.
estimates
Fundamentals updated 12 Nov 2026
Braveheart Bio, Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| FTRE Fortrea Holdings Inc. | $1.9B | — (loss-making) | — (loss-making) | −1.40% (below 0%: shrinking) | n/m | −33.96% (below 0%: shrinking) | 20.17% | 2.17% | Compare |
| TRVI Trevi Therapeutics, Inc. | $1.9B | — (loss-making) | — | — | n/m | −80.98% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| AGIO Agios Pharmaceuticals, Inc. | $1.9B | — (loss-making) | — (loss-making) | +330.01% (above 0%: growing) | n/m | +32.64% (above 0%: growing) | 95.44% | (139.32%) | Compare |
| LYCA Lycia Therapeutics Inc. | $1.9B | — | — | — | — | — | — | — | Compare |
| ZBIO Zenas BioPharma, Inc. | $1.9B | — (loss-making) | — (loss-making) | — | n/m | −41.00% (below 0%: shrinking) | 100.00% | (1,034.09%) | Compare |
| BRVE Braveheart Bio, Inc. | $1.8B | — (loss-making) | — | — | n/m | −3,193.65% (below 0%: shrinking) | — | 0.00% | |
| COAG Hemab Therapeutics Holdings, Inc. | $1.8B | — (loss-making) | — | — | n/m | −84.73% (below 0%: shrinking) | — | 0.00% | Compare |
| ZYME Zymeworks Inc. | $1.8B | 39.5× | 21.1× FY26e | +828.73% (above 0%: growing) | n/m | +24.23% (above 0%: growing) | 85.91% | 69.25% | Compare |
| QURE uniQure N.V. | $1.7B | — (loss-making) | — (loss-making) | +40.39% (above 0%: growing) | n/m | −192.89% (below 0%: shrinking) | 95.46% | (1,019.63%) | Compare |
| Median of peers | $1.9B | — | — | +185.20% | — | −41.00% | 90.68% | 0.00% |
Braveheart Bio, Inc. (BRVE) Latest News
What happened
- Jefferies starts biopharma firm Braveheart at Buy after IPO
- Braveheart Bio (BRVE) Raised $382.5 Million In Its IPO
- Braveheart Bio Announces Closing of Upsized Initial Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
- Braveheart Bio Announces Pricing of Upsized Initial Public Offering